Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eprosartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.91 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.91 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprosartan SCHEMBL4382102 | 1.00 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1504815 | 1.00 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL4382107 | 1.00 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL41397 | 0.99 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL41396 | 0.99 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL3972893 | 0.99 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL5785067 | 0.99 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL74813 | 0.96 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL7405236 | 0.96 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1119965 | 0.96 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0889880-B1 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORP (US) | 2003-05-07 | — | — | EP | claimed |
| US-6420412-B2 | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE AND RENAL FAILURE, BLOCKING ANGIOTENSIN II RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | claimed |
| US-20010031877-A1 | Eprosartan dihydate and a process for its production and formulation | SMITHKLINE BEECHAM CORPORATION | 2001-10-18 | — | — | US | claimed |
| EP-0889880-A4 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORP (US) | 1999-06-23 | — | — | EP | claimed |
| EP-0889880-A1 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| WO-1997036874-A1 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-09 | — | — | WO | claimed |
| US-8361507-B2 | Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan | HETERO DRUGS LIMITED (IN) | 2013-01-29 | — | — | US | disclosed |
| EP-1061803-B1 | COMPOSITIONS OF EPROSARTAN | GLAXOSMITHKLINE LLC (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2295430-A2 | Crystalline solid of eprosartan acetate | Hetero Drugs Limited (IN) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295431-A2 | Substantially pure eprosartan free base | Hetero Drugs Limited (IN) | 2011-03-16 | — | — | EP | disclosed |
| US-20100166850-A1 | EPROSARTAN MESYLATE CRYSTALLINE PARTICLES AND A PROCESS FOR PREPARING PURE EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2010-07-01 | — | — | US | disclosed |
| EP-2181109-A2 | EPROSARTAN MESYLATE CRYSTALLINE PARTICLES AND A PROCESS FOR PREPARING PURE EPROSARTAN | Hetero Drugs Limited (IN) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009084028-A2 | IMPROVED PROCESS FOR MANUFACTURING ANHYDROUS (E)-3-[2-BUTYL-1- {(4-CARBOXYPHENYL) METHYL}-1H-IMIDAZOLE-5-YL]-(THIOPHEN-2- YLMETHYL)PROP-2-ENOIC ACID METHANE SULFONATE | NEULAND LABORATORIES LTD (IN) | 2009-07-09 | — | — | WO | disclosed |
| US-6262102-B1 | USING THE COMPOUND TO BLOCK ANGIOTENSIN II RECEPTORS AND TO TREAT HYPERTENSION, CONGESTIVE HEART FAILURE AND RENAL FAILURE. | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-0889880-A4 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORP (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0889880-A4 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORP (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0889880-A1 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0889880-A1 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997036874-A1 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036874-A1 | EPROSARTAN DIHYDRATE AND A PROCESS FOR ITS PRODUCTION AND FORMULATION | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166850-A1 | EPROSARTAN MESYLATE CRYSTALLINE PARTICLES AND A PROCESS FOR PREPARING PURE EPROSARTAN | REN, EPOR, EDNRA | AGTR1 5/4885ABCC3 3241/4885ABCC2 3041/4885 |
| US-20010031877-A1 | Eprosartan dihydate and a process for its production and formulation | AGTR2, AGTR1, EDNRB | AGTR1 2/4885ABCC3 3403/4885ABCC2 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.